

References:

1. SKYRIZI (risankizumab) [Package Insert]. North Chicago, Ill.: AbbVie Inc.
2. Kristensen L.E., et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase2 3 KEEPsAKE 1 trial. *Ann Rheum Dis.* 2021; 0:1–7. doi: 10.1136/annrheumdis-2021-221019.
3. Östör A., et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. *Ann Rheum Dis.* 2021; 0:1–8. doi: 10.1136/annrheumdis-2021-221048.
4. Galezowski, A., et al. Rhumatisme psoriasique en France, du nourrisson à la personne âgée: données de deux études transversales multicentriques [Psoriatic arthritis in France, from infants to the elderly: Findings from two cross-sectional, multicenter studies]. *Ann Dermatol Venereol.* 2018;145(1):13-20. doi:10.1016/j.annder.2017.10.008.
5. Duarte GV, et al. Psoriatic arthritis. *Best Pract Res Clin Rheumatol.* 2012 Feb;26(1):147-56. doi: 10.1016/j.berh.2012.01.003.
6. Diseases & Conditions: Psoriatic Arthritis. 2019. American College of Rheumatology. Available at: <https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Psoriatic-Arthritis>. Accessed on December 15, 2021.
7. Psoriatic Arthritis. 2019. Mayo Clinic. Available at: <https://www.mayoclinic.org/diseases-conditions/psoriatic-arthritis/symptoms-causes/syc-20354076>. Accessed on December 15, 2021.
8. Duvallet E., Sererano L., Assier E., et al. Interleukin-23: a key cytokine in inflammatory diseases. *Ann Med.* 2011. Nov 43(7):503-11.
9. BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis. *ClinicalTrials.gov.* 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT02684370>. Accessed on December 14, 2021.
10. BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis. *ClinicalTrials.gov.* 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT02684357>. Accessed on December 14, 2021.
11. BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment. *ClinicalTrials.gov.* 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT02672852>. Accessed on December 14, 2021.
12. BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis. *ClinicalTrials.gov.* 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT02694523>. Accessed on December 14, 2021.
13. A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease. *ClinicalTrials.gov.* 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT03105128>. Accessed on December 14, 2021.
14. A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis. *ClinicalTrials.gov.* 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT03398135>. Accessed on December 14, 2021.
15. A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis. Available at: <https://clinicaltrials.gov/ct2/show/NCT03398148>. Accessed on December 14, 2021.
16. BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis. Available at: <https://clinicaltrials.gov/ct2/show/NCT03675308>. Accessed on December 14, 2021.



17.BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis.
Available at: <https://clinicaltrials.gov/ct2/show/NCT03671148>. Accessed on December 14, 2021.